Related Experiment Video
Updated: Jun 6, 2025
06:03
Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
7.9K
Using Computer Modeling and Experimental Methods to Screen for Aptamers That Bind to the VV-GMCSF-LACT Virus
Maya Dymova1, Natalia Vasileva1, Daria Malysheva1
1The Laboratory of Biotechnology, Institute of Chemical Biology and Fundamental Medicine SB RAS, 630090 Novosibirsk, Russia.
Molecules (Basel, Switzerland)
|November 27, 2024
Summary
Aptamers can shield oncolytic viruses from neutralizing antibodies, enhancing cancer therapy. This study identified aptamer candidates to protect VV-GMCSF-Lact viruses, improving their effectiveness.
Area of Science:
- Oncology
- Virology
- Biotechnology
Background:
- Oncolytic virotherapy shows promise for cancer treatment but is limited by virus-neutralizing antibodies.
- Aptamers can shield viruses from the immune system, but their efficacy depends on the specific viral strain.
Purpose of the Study:
- To develop and evaluate aptamers for shielding the VV-GMCSF-Lact vaccinia virus strain from neutralizing antibodies.
- To investigate the binding efficiency, cytotoxicity, and stability of aptamers against VV-GMCSF-Lact.
- To assess the synergistic effect of aptamer-shielded VV-GMCSF-Lact with human glioblastoma cells.
Main Methods:
- Molecular modeling to determine aptamer structures.
- In vitro studies to measure aptamer binding efficiency (EC50), cytotoxicity, and stability.
- Co-culture experiments with human glioblastoma cells to evaluate synergistic effects in serum.
Main Results:
- Spatial atomic structures of aptamers were determined using molecular modeling.
- Aptamer binding efficiency, cytotoxicity, and stability were characterized.
- Preliminary screening identified potential aptamer candidates capable of shielding VV-GMCSF-Lact from neutralizing antibodies.
Conclusions:
- A combined in silico and experimental approach enables preliminary screening of aptamer candidates.
- Identified aptamers show potential for protecting VV-GMCSF-Lact from immune neutralization, enhancing oncolytic virotherapy effectiveness.
